Alpha Tau Medical (NASDAQ:DRTS) Stock Keeps Buy Rating at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 21.90% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 1st. Finally, Barclays boosted their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.40.

Alpha Tau Medical Stock Up 4.0%

DRTS traded up $0.51 during trading on Tuesday, reaching $13.12. The stock had a trading volume of 270,948 shares, compared to its average volume of 581,893. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -12.62 and a beta of 1.22. The stock’s 50 day moving average is $14.47 and its two-hundred day moving average is $11.73. Alpha Tau Medical has a one year low of $3.43 and a one year high of $15.79.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). As a group, analysts expect that Alpha Tau Medical will post -1.05 earnings per share for the current year.

Insider Activity

In other news, CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the sale, the chief financial officer owned 90,180 shares in the company, valued at $1,352,700. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

Large investors have recently bought and sold shares of the business. Everhart Financial Group Inc. bought a new position in shares of Alpha Tau Medical in the 2nd quarter valued at about $126,000. Renaissance Technologies LLC bought a new stake in Alpha Tau Medical during the first quarter worth approximately $286,000. Finally, Principal Financial Group Inc. bought a new stake in Alpha Tau Medical during the first quarter worth approximately $132,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.